Vion Pharmaceuticals to Implement a One-for-Ten Reverse S... (added We will now continue to moveforwa...)

Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split

Date:2/20/2008

added, "We will now continue to move forward towards our goal of filing a New Drug Application for Cloretazine(R) (VNP40101M) in 2008."

This action follows shareholder approval, at a Special Meeting of Stockholders held on February 13, 2008, of the grant of discretionary authority to the Board to implement a reverse stock split and decrease the total numbers of shares and the number of shares of common stock the Company is authorized to issue. The Board determined the exact ratio of the reverse split at a meeting of the Board on February 19, 2008.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a pivotal Phase II trial as a single agent in elderly patients with de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety a
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
2. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
3. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
4. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
5. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
7. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Keryx Biopharmaceuticals Announces Additions to Management Team
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results

Post Your Comments:

Vion Pharmaceuticals to Implement a One-for-Ten Reverse S...(added We will now continue to moveforwa...)